GZMB and neoplasm: Type I IFNs also directly enhance CD8+ T cell responsiveness to cognate antigens [181,182] and stimulate the acquisition of CTL effector function through activating the STAT3-Granzyme B (GzmB) pathway, thus ensuring tumor suppression [183].